The NeurologyLive® multiple sclerosis (MS) clinical focus page offers information, podcasts, videos, and news about the latest study and clinical trial findings, FDA actions, clinical guideline updates, and expert interviews related to the care and management of patients with MS, including relapsing MS and progressive MS, as well as related disorders such as neuromyelitis optica spectrum disorder.
Check out some of NeurologyLive®'s featured content in the carousel below.
Institutional Perspectives in Neurology, Chaired by Robert T. Naismith, MDNovember 10th 2022
Chaired by Robert T. Naismith, MD, of Washington University in St. Louis, the presentations also feature Salim Chahin, MD, MSCE; Anne H. Cross, MD; Gregory F. Wu, MD, PhD; and Matthew R. Brier, MD, PhD. [WATCH TIME: 1 hour, 55 minutes]
Occurrence of Late-Onset Neurotropenia After Anti-CD20 Therapy: Tianrong Yeo, PhD, MBBS, MRCP, MMED, FAMS, MCINovember 9th 2022
The senior consultant for the department of neurology at the National Neuroscience Institute discussed a report on two patients who developed an uncommon adverse event of late-onset neurotropenia after anti-CD20 therapy treatment. [WATCH TIME: 8 minutes]
Advocacy and Empowerment: Finding Your Advocacy CommunityNovember 9th 2022
The Palatucci Advocacy Leadership Forum, or PALF, sponsored by the American Academy of Neurology, gives neurologists and trainees tools to successfully advocate for their ideas and develop their identity as physician advocates.
NeuroVoices: Bruce Cree, MD, PhD, MAS, FAAN, on the Importance of Biomarker Studies in NMO and Role of NfL, GFAPNovember 9th 2022
The clinical research director of the UCSF Multiple Sclerosis Center provided perspective on several analyses from the N-MOmentum trial that highlight the clinical use of biomarkers in NMO and NMOSD.
The Inflation Reduction Act and Lowering the Economic Burden of MS in the United States: Bari Talente, JDNovember 8th 2022
The executive vice principal of advocacy and healthcare access at the National MS Society offered a brief overview of the Inflation Reduction Act of 2022 and how it relates to the economic impact faced by patients with MS. [WATCH TIME: 5 minutes]
Role of Serum Neurofilament Light in Predicting Neuromyelitis Optica Attacks: Bruce Cree, MD, PhD, MAS, FAANNovember 8th 2022
The clinical research director of the UCSF Multiple Sclerosis Center provided perspective on the importance of serum neurofilament light and how it can be used in the management of patients with NMOSD. [WATCH TIME: 3 minutes]
Telehealth and Digital Measures May Assist With Monitoring MS Progression: Marisa McGinley, DONovember 7th 2022
The staff neurologist at the Mellen Center for MS Treatment and Research at Cleveland Clinic spoke about her presentation from ECTRIMS 2022 on teleneurology and its utilization as a tool to make care more accessible to patients with MS. [WATCH TIME: 7 minutes]
Advocacy in Neurology: A Tool to Serve and Find FulfillmentNovember 7th 2022
Acting as an advocate is meaningful to neurologists because it speaks to their inner core—or their “why.” Neurologists have the agency to make this world a better place while working as a neurologist and an advocate at many levels.
Teleneurology Overcomes Health Disparities and Improves Accessibility in MS: Marisa McGinley, DONovember 6th 2022
The staff neurologist at the Mellen Center for MS Treatment and Research at Cleveland Clinic, spoke about her presentation on teleneurology being a beneficial healthcare tool for patients with MS at ECTRIMS 2022. [WATCH TIME: 7 minutes]
Critical Aspects of Treatment During Postpartum in Patients with MS, NMOSD: Riley Bove, MDNovember 3rd 2022
The associate professor of neurology at the University of California, San Francisco, discussed the key points from an oral presentation at ECTRIMS 2022 on understanding postpartum for patients with MS and NMOSD. [WATCH TIME: 4 minutes]
Emerging Biomarkers to Consider for NMOSD, Neuromyeltis Optica: Bruce Cree, MD, PhD, MAS, FAANNovember 3rd 2022
The clinical research director of the UCSF Multiple Sclerosis Center discussed the need for measures of progression in neuromyelitis optica and the next steps in treatment. [WATCH TIME: 4 minutes]
Positive Safety Profile of Anti-CD20 Therapy During Postpartum in MS, NMOSD: Riley Bove, MDNovember 2nd 2022
The associate professor of neurology at the University of California, San Francisco, discussed takeaways from an oral presentation at ECTRIMS 2022 on the use of anti-CD20 therapies in postpartum for patients with MS and NMOSD. [WATCH TIME: 5 minutes]
Inebilizumab’s Impact on B-Cells, Plasmablasts, and Plasma Cells in NMOSD: Bruce Cree, MD, PhD, MAS, FAANNovember 2nd 2022
The clinical research director of the UCSF Multiple Sclerosis Center provided insight on an abstract from ECTRIMS 2022 regarding inebilizumab’s mechanism of action to prevent NMOSD attacks. [WATCH TIME: 3 minutes]
Ocrelizumab’s Impact on Humoral Response to EBV: Robert Zivadinov, MD, PhDNovember 1st 2022
The director of the Buffalo Neuroimaging Analysis Center provided context on a new study exploring ocrezliumab’s (Ocrevus; Genentech) effect on leptomeningeal inflammation and humoral response to EBV. [WATCH TIME: 5 minutes]
Using Clinically Pertinent Neuromuscular Function Assessments to Predict Falls in Multiple SclerosisNovember 1st 2022
Laurits Taul Madsen, a PhD candidate at Aarhus University, discussed the use of lower extremity function assessments to characterize patients with MS at risk for future falls.
Capabilities of Stem Cell Transplantation vs Other Relapsing MS Therapies: Tomas Kalincik, MD, PhDNovember 1st 2022
The professor of neurology and biostatistician at University of Melbourne and Royal Melbourne Hospital spoke on stem cell transplantation in patients with MS and its effectiveness in comparison with other traditional approaches. [WATCH TIME: 2 minutes]
Paleolithic and Mediterranean Diets Show Greatest Impact on QoL, Fatigue in Multiple SclerosisNovember 1st 2022
In the meta-analysis, the Paleolithic and Mediterranean diets continued to outperform other dietary interventions such as ketogenic, anti-inflammatory, fasting, and calorie restriction on fatigue and quality-of-life outcomes.
Antibody Levels in Evobrutinib-Treated Relapsing Multiple Sclerosis Increased Following COVID-19 VaccinationOctober 31st 2022
Findings from a randomized phase 2 trial resulted in patients with relapsing multiple sclerosis treated with evobrutinib displaying an increase in S1/S2 IgG antibody levels.
Therapeutic Focuses of MS and the Need to Reach NEDA Status: Stuart Silverman, MDOctober 31st 2022
As the treatment landscape for relapsing MS continues to strengthen, the neurologist at Allegheny Health Network discussed the reasons for continued pursuit of drug development. [WATCH TIME: 3 minutes]
Choosing Between Stem Cell Transplantation or Fingolimod to Treat Highly Active MS: Tomas Kalincik, MD, PhDOctober 31st 2022
The professor of neurology and biostatistician at the University of Melbourne and Royal Melbourne Hospital spoke about his oral presentation from the 38th ECTRIMS Congress. [WATCH TIME: 5 minutes]
Early Intervention of Highly-Effective DMTs Results in Higher Probability of Achieving NEDA-3October 30th 2022
Among those on early highly-effective treatments, shorter disease duration and shorter time between first treatment and current treatment led to more patients achieving no evidence of disease activity.
Using Neuromuscular Function as a Risk Factor for Falls in Multiple Sclerosis: Laurits Taul Madsen, PhD-COctober 30th 2022
The PhD student at Aarhus University provided insight on his study presented at 2022 ECTRIMS Congress on an innovative way using neuromuscular measures to discriminate those with MS at high risk for falls. [WATCH TIME: 2 minutes]